Company news

Enliven Therapeutics, Inc. news in 2021

Enliven Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH) Annual Meeting 2021

December 13, 2021

Imara Presents Clinical and Preclinical Tovinontrine (IMR-687) Data at the American Society of Hematology (ASH) Annual Meeting 2021

December 12, 2021

Imara Announces Primary Endpoint Change in the Ardent Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Sickle Cell Disease

November 21, 2021

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine (IMR-687) in Transfusion-Dependent Subjects with Beta-thalassemia

November 15, 2021

Imara Reports Third Quarter 2021 Financial Results and Business Highlights

November 8, 2021

Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

November 7, 2021

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

November 3, 2021

Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021

November 3, 2021

Imara to Participate in Upcoming Investor Conferences

September 14, 2021

Imara to Present at Upcoming Investor Conferences

September 2, 2021

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

August 5, 2021

Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease

August 4, 2021

Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

July 29, 2021

Imara Announces Pricing of Public Offering

July 12, 2021

Imara Announces Launch of Proposed Public Offering

July 12, 2021

Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

June 29, 2021

Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders

June 16, 2021

Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

June 10, 2021

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

June 3, 2021

Imara Reports First Quarter 2021 Financial Results and Business Highlights

May 10, 2021

Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights

May 3, 2021

Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders

March 28, 2021

Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia

March 16, 2021

Imara Reports Full Year 2020 Financial Results and Business Highlights

March 4, 2021

Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights

February 25, 2021

Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference

February 18, 2021

Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

January 19, 2021

Imara Reports Phase 2a Clinical Trial Results of IMR-687 in Adult Patients with Sickle Cell Disease

January 5, 2021

Calls in 2021